Aldeyra Therapeutics, Inc. (ALDX) Financials
ALDX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 147.3 million | 24.3 million |
2023-06-30 | 155.6 million | 25.7 million |
2023-03-31 | 168.2 million | 31.0 million |
2022-12-31 | 181.3 million | 30.3 million |
ALDX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -8.0 million | 789216 |
2023-06-30 | -13.4 million | 1.6 million |
2023-03-31 | -9.4 million | 4.2 million |
2022-12-31 | -11.2 million | 2.8 million |
ALDX Net Income
No data available :(
ALDX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 143.3 million | - | 65628 |
2023-06-30 | 151.7 million | - | 129785 |
2023-03-31 | 165.0 million | 15.0 million | 190202 |
2022-12-31 | 174.3 million | 14.9 million | 249265 |
ALDX Shares Outstanding
ALDX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | - | 7.0 million | 2.6 million | - |
2023-06-30 | - | 7.0 million | 3.4 million | - |
2023-03-31 | - | 11.2 million | 5.6 million | - |
2022-12-31 | 16317 | 9.0 million | 4.7 million | - |
ALDX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | 64999 |
2023-06-30 | - | 64339 |
2023-03-31 | - | 66972 |
2022-12-31 | - | 66643 |
ALDX
Price: $4.21
52 week price:
Earnings Per Share: -0.64 USD
P/E Ratio: -4
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 79624
Ebitda: -4.9 millionMarket Capitalization: 250.3 million